RxDoctor Payments Data

Rance Wilbourn, MD

Neurology · Germantown, TNNPI 1063676690

Payments from drug & device makers

$52,377in general payments, 2019–2025

Across 1,566 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$26K
  • Novartis$3K
  • SK Life Science, Inc.$2K
  • EMD Serono, Inc.$2K
  • UCB, Inc.$1K
  • Biogen$1K
  • plus $17K from 54 others

What the payments were for

  • Speaking & faculty fees$18,95036%
  • Travel & lodging$2,5565%
  • Food & beverage$30,62258%
  • Education$2500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)227$25,853
Novartis133$2,712
SK Life Science, Inc.71$1,789
EMD Serono, Inc.88$1,738
UCB, Inc.67$1,408
Biogen67$1,383
Pfizer88$1,214
Lilly USA, LLC67$1,113
Argenx US, Inc.38$1,030
Lundbeck LLC42$977
Amgen(2 entities)53$919
Eisai Inc.52$916
AstraZeneca(2 entities)31$889
Neurocrine Biosciences, Inc.37$847
Amneal Pharmaceuticals LLC53$825
Teva Pharmaceuticals USA, Inc.37$717
Acadia Pharmaceuticals Inc26$687
CSL Behring40$665
Biohaven Pharmaceutical Holding Company Ltd.55$607
ANI Pharmaceuticals, Inc.18$550
Bristol Myers Squibb27$520
Upsher-smith Laboratories LLC28$484
Biohaven Pharmaceuticals, Inc.39$478
Genentech USA, Inc.21$384
Sunovion Pharmaceuticals Inc.23$351
Banner Life Sciences, LLC19$329
MDD US Operations, LLC10$238
Tanabe Pharma America, Inc.12$228
Neurelis, Inc.10$197
Hydrofera LLC2$177
Supernus Pharmaceuticals, Inc.10$167
Sanofi7$164
Idorsia Pharmaceuticals US Inc5$150
TG Therapeutics, Inc.5$140
Currax Pharmaceuticals LLC10$137
Nevro Corp.1$135
Otsuka America Pharmaceutical, Inc.2$133
Sumitomo Pharma America, Inc.3$133
Johnson & Johnson(2 entities)3$128
E.r. Squibb & Sons, L.L.C.1$123
Grifols USA, LLC5$88
Merz Pharmaceuticals, LLC2$66
Scilex Pharmaceuticals Inc.3$63
GRT US Holding, Inc.3$53
Kyowa Kirin, Inc.3$50
Almatica Pharma LLC3$47
Livanova USA, Inc.2$41
Aquestive Therapeutics, Inc.2$30
Jazz Pharmaceuticals Inc.1$29
Alnylam Pharmaceuticals Inc.1$28
Vanda Pharmaceuticals Inc.1$28
C2n Diagnostics, LLC1$26
Novo Nordisk1$22
Insightec,inc1$20
Ipsen Biopharmaceuticals, Inc1$19
Axsome Therapeutics, Inc.1$19
Acorda Therapeutics, Inc1$19
Greenwich Biosciences, Inc.1$18
Averitas Pharma Inc.1$17
Avanir Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,377 in reported general payments places this provider in the 80th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$318,634
Medicare patients
811
Services billed
11,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$463,751
GammakedImmune Globul G/Gly/Iga Avg 4613$213,647
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$194,171
BetaseronInterferon Beta-1b12$112,080
BotoxOnabotulinumtoxina58$106,309
RytaryCarbidopa/Levodopa43$35,688
Emgality PenGalcanezumab-Gnlm37$28,166
XcopriCenobamate19$24,439
NuedextaDextromethorphan Hbr/Quinidine12$18,136
Aimovig AutoinjectorErenumab-Aooe20$14,921
Pregabalin79$2,099
Memantine Hcl106$1,947
Levetiracetam45$1,599
Gabapentin107$1,574
Donepezil Hcl169$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$1,214$194,17113 claims
AbbVieBotox$25,853$106,30958 claims
Amneal Pharmaceuticals LLCRytary$825$35,68843 claims
SK Life Science, Inc.Xcopri$1,789$24,43919 claims
Avanir Pharmaceuticals, Inc.Nuedexta$16$18,13612 claims
Almatica Pharma LLCSertraline Hcl$47$18526 claims
Upsher-smith Laboratories LLCTopiramate$484$11412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 neurology providers in Tennessee.

Other neurology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →